DePuy said it’s released a pair of products, featuring the integration of Brainlab’s software with its Viper 2 pedicle screw system and its Expedium spine system. And there’s more to come, according to a press release.
"We believe the use of our instrumentation with Brainlab’s imaging and navigation solutions will be highly attractive to customers globally," DePuy Synthes Spine president Namal Nawana said in prepared remarks. "This partnership is the latest example of how our new company is providing procedural solutions that deliver benefits to patients, physicians, providers, payers and policy makers."
"The partnership with DePuy Synthes Spine will allow us to integrate our technology seamlessly in surgical procedures and therefore provide an unmatched product offering to our combined customers," added Brainlab president & CEO Stefan Vilsmeier.
Stealthy Medina Medical reels in $7M
Medina Medical, a medical device company out of Mountain View, Calif., that’s still in stealth mode, raised more than $6.5 million from a group of 28 unnamed investors, according to a regulatory filing.
Bard prices $500M debt offering
C.R. Bard (NYSE:BCR) priced a public offering of $500 million worth of 5-year senior notes at an interest rate of 1.375%. S&P gave the offering an “A” rating, while competitor Moody’s Investors Service gave the issue an “A3” rating.
Moody’s upgrades Abbott, S&P cuts rating
Moody’s Investors Service
upgraded its rating on Abbott (NYSE:ABT) from "negative" to "stable," but rival S&P cut its rating on ABT from "AA" to "A+." S&P also rated Abbott’s soon-to-be branded pharma spinout, AbbVie, at "A."